- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05954325
Immunoadsorption vs. Sham Treatment in Post COVID-19 Patients With Chronic Fatigue Syndrome
February 22, 2024 updated by: Hannover Medical School
Extracorporal Apheresis Hannover Medical School Study in Post COVID-19 Patients
The complex clinical symptoms of post COVID syndrome, especially chronic fatigue, pose a major challenge to patients and to the health care system and are frequently refractory to therapeutic intervention.
There is increasing evidence that a dysregulated post-viral immune response may be involved in the pathogenesis of post COVID syndrome.
In uncontrolled case studies, an improvement of fatigue symptoms after removing autoantibodies has been reported in post COVID patients.
However, there is a lack of prospective, sham controlled studies.
We initiate an interventional, randomised, sham treatment-controlled prospective study, the EXTINCT post COVID study, which aims to scientifically test the therapeutic efficacy of an extracorporeal apheresis procedure (immunoadsorption) for the treatment of a well characterized cohort of patients with post COVID syndrome, while at the same time providing basic research evidence for an understanding of the pathogenesis of post COVID syndrome.
Thereby, we expect to obtain important insights into the diagnosis, treatment and pathophysiology of post-COVID syndrome.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dr. Goedecke, MD
- Phone Number: 3000 0049-511-532-0
- Email: studienzentrum@mh-hannover.de
Study Contact Backup
- Name: Prof. Schmidt, MD
- Phone Number: 3000 0049-511-532-0
- Email: studienzentrum@mh-hannover.de
Study Locations
-
-
Lower Saxony
-
Hannover, Lower Saxony, Germany, 30625
- Recruiting
- Hannover Medical School
-
Contact:
- Hannover Medical School
- Phone Number: 3000 0049-511-532-0
- Email: studienzentrum@mh-hannover.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18-75 years
- Chronic Fatigue Syndrome (CFS) according to Canadian Consensus Criteria (at two time points > 4 weeks apart) with a duration of > 6 months with new onset < 12 weeks after PCR test confirmed SARS-CoV2-infection
- Chalder Fatigue Scale >/= 4 binary scale (at two time points > 4 weeks apart)
- Post exertional malaise >/= 14 h (at two time points > 4 weeks apart)
- Bell Scale 20-50 (at two time points > 4 weeks apart)
- Willing to comply with all aspects of the protocol, including blood draws, magnetic resonance imaging and ophthalmological evaluation
- Patient is able to understand and fully participate in the activities of the study and consent in accordance with guidelines
- Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception. Female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire period.
Exclusion citeria:
- Chronic fatigue due to other medical or psychological condition
- Preexisting chronic fatigue prior to COVID infection
- Oxygen requirement or ventilation during acute phase of COVID
- Positive SARS-CoV-2-PCR test at the beginning of the study
- Comorbidity bearing risk that patient might not tolerate treatment as judged by investigator including among others: malignant disease within the last 5 years, moderate to severe renal impairment (eGFR <60 ml/min), cardiac insufficiency (LVEF <40%), severe coronary heart disease, severe hypercoagulability
- Acute or severe psychiatric disease
- Active/acute infectious diseases like CMV, EBV, HBV, HCV, HIV, TBC
- Patients who in the investigator's opinion might not be suitable for study (difficult peripheral venous access, not able to complete questionnaires e.g. due to language problems)
- Taking immunosuppressive medication >3 weeks within 12 months before study inclusion
- Any apheresis therapy before study inclusion
- Contraindications for magnetic resonance imaging
- Patients revealing abnormal brain structures visible in MR images
- Patients with pre-existing ophthalmological condition or diabetes mellitus
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Immunoadsorption
5 immunoadsorption treatments
|
5 treatments within 14 days
Other Names:
|
Sham Comparator: Sham immunoadsorption
5 sham immunoadsorption treatments
|
5 treatments within 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chalder Fatigue Scale
Time Frame: 12 weeks
|
Time course of fatigue symptoms as determined based on Chalder Fatigue Scale (ranging from 0 to 33), higher values indicating a higher burden of fatigue symptoms
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of health status
Time Frame: 12 weeks
|
Evaluation of health status by Short Form Health Survey (SF-36)
|
12 weeks
|
Depression and Anxiety
Time Frame: 12 weeks
|
Symptoms of depression and anxiety measured by Hospital Anxiety and Depression Scale (HADS)
|
12 weeks
|
6-min. walk test
Time Frame: 12 weeks
|
Walking distance, oxygen saturation, heart rate and dyspnea assessed during 6-min.
walk test
|
12 weeks
|
Hand grip strength
Time Frame: 12 weeks
|
Hand grip strength measured via digital hand dynamometer
|
12 weeks
|
Cranial magnetic resonance imaging and spectroscopy
Time Frame: 12 weeks
|
Cranial magnetic resonance imaging and assessment of region-dependent metabolic distributions
|
12 weeks
|
Neurocognitive function
Time Frame: 12 weeks
|
Attentional deficits as assessed by Test of Attentional Performance
|
12 weeks
|
Cognitive Function
Time Frame: 12 weeks
|
Assessment of cognitive function measured by Montreal Cognitive Assessment (Scale 0-30), lower values indicating cognitive impairment
|
12 weeks
|
Post exertional malaise symptoms
Time Frame: 12 weeks
|
Assessment of frequency and severity of post exertional malaise symptoms (frequency: 0-20, severity: 0-20, duration), higher values indicating a higher burden of post exertional malaise symptoms
|
12 weeks
|
Autonomic dysfunction
Time Frame: 12 weeks
|
Symptoms of autonomic dysfunction assessed by Composite Autonomic Symptom Score (COMPASS 31), generating a weighted score from 0 to 100, with higher scores representing higher symptom burden
|
12 weeks
|
Optical coherence tomography angiography
Time Frame: 12 weeks
|
Assessment of retinal microcirculation
|
12 weeks
|
Symptoms related to chronic fatigue before and after immunoadsorption
Time Frame: 12 weeks
|
Change of symptoms as measured by Fluge score, using a scale ranging from 1 to 10 (higher values representing higher symptom load) assessing 32 fatigue related symptoms and their intra-patient change from baseline to follow-up
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of immunoadsorption treatment
Time Frame: 12 weeks
|
Number of treatment emergent adverse events, serious adverse events and discontinuation due to treatment emergent adverse events
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dr. Goedecke, MD, Hannover Medical School, Department of Nephrology and Hypertension
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
July 19, 2023
First Submitted That Met QC Criteria
July 19, 2023
First Posted (Actual)
July 20, 2023
Study Record Updates
Last Update Posted (Estimated)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Disease
- Chronic Disease
- Post-Infectious Disorders
- COVID-19
- Syndrome
- Fatigue
- Post-Acute COVID-19 Syndrome
Other Study ID Numbers
- EXTINCT post COVID
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
University of ZurichRecruitingVocal FatigueSwitzerland
-
KU LeuvenCompleted
-
Société des Produits Nestlé (SPN)Maastricht University Medical CenterCompleted
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
Taoyuan General HospitalCompleted
-
Alaa Yousri Mahmoud AtiaUnknownMuscle FatigueEgypt
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...CompletedNeuromuscular FatigueFrance
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Institut National de Recherche et de Sécurité, Nancy...Unknown
Clinical Trials on Immunoadsorption vs. sham immunoadsorption
-
University Medicine GreifswaldBristol-Myers Squibb; Krupp von Bohlen und Halbach-Foundation, Essen, Germany; ENDI-Foundation, Bad Homburg, GermanyCompletedDilated CardiomyopathyGermany, Serbia, Sweden
-
Nanjing University School of MedicineCompleted
-
Manchester University NHS Foundation TrustFresenius AGCompletedAutoimmune Membranous NephropathyUnited Kingdom
-
University Medical Center GroningenFresenius Medical Care North AmericaCompletedAnti-glomerular Basement Membrane GlomerulonephritisNetherlands
-
Albert Christian Ludolph, Prof.CompletedMultiple Sclerosis | Clinically Isolated SyndromeGermany
-
Charite University, Berlin, GermanyRecruitingImmunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFSME/CFS | Post-COVID ME/CFSGermany
-
University of LuebeckCompleted
-
University Medical Center MainzRecruitingPost-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID SyndromeGermany
-
Miltenyi Biotec B.V. & Co. KGCompletedIdiopathic Pulmonary Arterial HypertensionGermany
-
Wuhan Union Hospital, ChinaUnknownDilated CardiomyopathyChina